AIM adds supply chain leader Thomas Ebel to its partner team

01 June 2026 Consultancy.eu

AIM has strengthened its senior team with Thomas Ebel, a veteran pharma supply chain expert who joins as a partner.

Based in Germany, Thomas Ebel brings more than 25 years of supply chain consulting experience at leading firms including Accenture, Camelot (acquired by Accenture in 2024), and McKinsey & Company. He has extensive experience in supply chain strategy, design and network optimization, digital innovation, and advanced analytics.

“What Thomas brings in end-to-end supply chain strategy and optimization complements what AIM already does exceptionally well. We’re delighted to have him on board,” said Richard de Bakker, director and founder at AIM.

Founded in 2009, AIM is an award-winning supply chain consultancy focused on the life sciences sector. The company, which is part of US-headquartered Blue Matter, helps a broad range of pharmaceutical and biotech companies with optimizing their supply chains.

At AIM, Ebel will play a key role in expanding the firm’s capabilities and supporting business and team growth. “I was attracted to AIM by a rare combination,” he said about his appointment. “Genuine deep expertise in life science supply chain and distribution, a hands-on pragmatic approach, and a team of consultants who have actually done the work. The track record speaks for itself, and I’m excited to get started.”

According to De Bakker, Ebel’s arrival continues the investments the firm is making in expanding its end-to-end supply chain capabilities. “AIM is well known as a leader in supply chain development for launch, as well as optimization of existing supply chains – supporting clients in getting their finished products to patients.”

“We are now adding new capabilities in supply chain diagnostics and strategy, end-to-end planning optimization, supply reliability, and working capital optimization, among others. Combined with AIM’s established supply chain expertise, this expanded offering gives clients true end-to-end support, from source to patient.”